Durham pharma lands $2.5M from NIH to target Alzheimer’s disease


A Durham pharmaceutical company has landed a $2.5 million award from the federal government to advance its treatment for Alzheimer's disease.

Previous Another major subdivision proposed in fast-growing Durham suburb
Next Denver housing market approaching balance for first time in 16 years, say Realtors